Dry Eye

A look back on what's happened in optometry during the week of Jan. 14-Jan. 19.

Staying up-to-date on all things ocular is imperative in ocular surface disease.

Novel drops for a variety of indications are under investigation.

A look back on what's happened in optometry during the week of Jan. 7-Jan. 12, 2023.

Patient quality of life has been shown to be severely impaired by the associated ocular surface symptoms, so treatment aims for symptomatic relief and prevention of further damage to the ocular surface.

A look back on what's happened in optometry during the week of Jan. 1-Jan. 5, 2023.

Diagnosing and treating dry eye and meibomian gland dysfunction can be the foundation for practice growth—and patient satisfaction.

Marc R. Bloomenstein, OD, FAAO, gives an overview of the SAHARA study.

Selina McGee, OD, FAAO, founder and owner of BeSpoke Vision in Edmond, Oklahoma, shares key takeaways from her discussion, "Pro- and Anti-Inflammatory Cytokine Levels in Tears of Dry Eye Subjects,“ which she presented during the 2022 American Academy of Optometry meeting in San Diego.

Pinakin Davey, PhD, OD, FAAO, gives key highlights from his AAOpt 2022 presentation, "Management of digital eye strain: comprehensive strategy and nutritional approach."

Jim Sluck, VP of Marketing for Sight Sciences' TearCare, shares the impetus behind the company's fair access campaign.

Nidhi Rana, OD, discusses key highlights from her AAOpt 2022 presentation on pediatric red eye.

Derek Cunningham, OD, FAAO, gives key takeaways from his AAOpt 2022 discussion, "Back to the basics: The importance of treating inflammation AND obstruction for dry eye."

When combined, intense pulsed light and low-level light therapy—both of which have roots in dermatology—create a synergistic effect that treat dry eye more effectively than one therapy alone.

Modern technology enables early detection, individualized solutions.

Preservative-free eye drops offer benefits for ocular health.

Katherine M. Mastrota, OD, FAAO, advises on how to diagnosis this condition and not fall prey to a “knee-jerk” dry eye diagnosis.

When oral acne treatments lead to ocular surface disease, the solution lies in office-based therapies.

Azura has secured funding to support its 2-stage study evaluating the safety, tolerability, and efficacy of AZR-MD-001, its leading candidate, for patients with contact lens discomfort who show signs of meibomian gland dysfunction.

Bausch + Lomb and Novaliqu announced that the FDA has accepted its New Drug Application for NOV03, an investigational treatment for dry eye disease associated with meibomian gland dysfunction.

FDA-approved steroid offers short-term relief for ocular surface inflammation.

Ensure successful symptoms management with your patients.

Latest transaction, totaling approximately $770 million, adds key commercial products and clinical/preclinical product candidates in the pipeline.

COMET-3 is the second of 3 studies in the AR-15512 Registrational Phase 3 Program, which is slated for completion by 2023.

One OD shares his experience launching a successful social media campaign for Dry Eye Awareness month—and offers 3 tips for crafting a message to capture an audience's attention.